ACRX stock news

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 30.43% and -39.37%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock? Read more
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more
REDWOOD CITY, Calif., July 1, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Company has been added as a member of Read more
AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Read more
ACRX earnings call for the period ending March 31, 2019. Read more
The pharma announced first-quarter 2019 operating results. Read more
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q1 2019 Earnings Conference Call May 08, 2019 04:30 PM ET Company Participants Raffi Asadorian - Chief Financial Offi Read more
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 26.09% and -68.64%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock? Read more
We expect AcelRx (ACRX) to provide update on the launch of its newly approved drug DSUVIA, when it reports first-quarter 2019 results. Read more
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more

Proudly made at

ROCKIT